Eli Lilly & Co
LLY
ISIN null / Valor 947556
Eli Lilly & Co
UMushroom community rating:
About company
Eli Lilly & Co, headquartered in Indianapolis, is a global pharmaceutical company with a significant presence in the healthcare sector. Known for its research, development, and commercialization of pharmaceutical products, Eli Lilly focuses on a wide range of therapeutic areas including but not limited to oncology, diabetes, neurodegeneration, and immunology. The company has recently announced results from a pioneering study of lebrikizumab, a treatment specifically designed for individuals with skin of color suffering from moderate-to-severe atopic dermatitis, also known as eczema. This highlights Eli Lilly's commitment to addressing diverse medical needs and expanding its portfolio to include treatments tailored for specific demographic groups. The company's efforts in innovation and targeted research underscore its role in advancing medical treatments and improving patient outcomes across various disease states.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (20.10.2025):
Eli Lilly & Co reported strong financial results for the fourth quarter of 2023, showcasing significant revenue and earnings growth driven by robust performance in both new and growth products. The company also provided optimistic guidance for 2024, reflecting continued expansion and strategic advancements in its pipeline and business operations.
Revenue Growth
In Q4 2023, Eli Lilly & Co achieved a 28% increase in revenue, reaching $9.35 billion compared to $7.30 billion in Q4 2022. This growth was fueled by a substantial rise in new products revenue, which grew by $2.19 billion to $2.49 billion, and growth products revenue, which increased by 9% to $5.27 billion.
Earnings Performance
The company's earnings per share (EPS) saw a notable increase of 13% to $2.42 on a reported basis and 19% to $2.49 on a non-GAAP basis. These earnings figures include $0.62 of acquired in-process research and development (IPR&D) charges, reflecting the company's strategic investments.
Product and Pipeline Advancements
New product launches such as Mounjaro and Zepbound led the growth in new products revenue. Additionally, Eli Lilly & Co made significant pipeline progress with the FDA approval of Zepbound for obesity treatment and Jaypirca for chronic lymphocytic leukemia. Positive results from the SYNERGY-NASH Phase 2 study also highlight the company's commitment to advancing its therapeutic portfolio.
Business Acquisitions
Eli Lilly & Co completed strategic acquisitions of POINT Biopharma Global Inc. and Mablink Biosciences SAS during Q4 2023, enhancing its capabilities and expanding its product offerings in the biopharmaceutical sector.
2024 Financial Guidance
The company provided its 2024 financial outlook, projecting revenue in the range of $40.4 billion to $41.6 billion, EPS between $11.80 to $12.30, and non-GAAP EPS from $12.20 to $12.70. This guidance underscores Eli Lilly & Co's confidence in sustaining its growth trajectory and continuing its investment in research and development.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
986309 M
Market cap (USD)
3,135,742
Daily traded volume (Shares)
779.59 / 771.02
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Tommaso Nebuloni
Jay Coles
Mueed Parkar
EQUITIES OF THE SAME SECTOR
